DK1051159T3 - Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis - Google Patents

Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis

Info

Publication number
DK1051159T3
DK1051159T3 DK98904121T DK98904121T DK1051159T3 DK 1051159 T3 DK1051159 T3 DK 1051159T3 DK 98904121 T DK98904121 T DK 98904121T DK 98904121 T DK98904121 T DK 98904121T DK 1051159 T3 DK1051159 T3 DK 1051159T3
Authority
DK
Denmark
Prior art keywords
leishmaniasis
treatment
oral administration
solid pharmaceutical
fosin
Prior art date
Application number
DK98904121T
Other languages
Danish (da)
English (en)
Inventor
Juergen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Application granted granted Critical
Publication of DK1051159T3 publication Critical patent/DK1051159T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98904121T 1998-01-22 1998-01-22 Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis DK1051159T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
DK1051159T3 true DK1051159T3 (da) 2002-08-05

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98904121T DK1051159T3 (da) 1998-01-22 1998-01-22 Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis

Country Status (24)

Country Link
US (1) US6544551B1 (de)
EP (1) EP1051159B1 (de)
JP (1) JP2002501015A (de)
KR (1) KR100517399B1 (de)
CN (1) CN100413492C (de)
AT (1) ATE215817T1 (de)
AU (1) AU756805B2 (de)
BR (1) BR9814772A (de)
CA (1) CA2318260C (de)
CZ (1) CZ299229B6 (de)
DE (1) DE69804865T2 (de)
DK (1) DK1051159T3 (de)
ES (1) ES2175663T3 (de)
HU (1) HUP0004363A3 (de)
IL (1) IL136196A (de)
NO (1) NO20003674D0 (de)
NZ (1) NZ505648A (de)
PL (1) PL189654B1 (de)
PT (1) PT1051159E (de)
SI (1) SI1051159T1 (de)
SK (1) SK284839B6 (de)
TR (1) TR200001717T2 (de)
UA (1) UA68372C2 (de)
WO (1) WO1999037289A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
PT1545553E (pt) * 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
DK1799196T3 (en) 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
BR112013012652A2 (pt) 2010-11-22 2016-09-06 Dafra Pharma Res & Dev Bvba forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida
BR112013033309B1 (pt) 2011-06-24 2022-07-05 Gri Bio, Inc Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i
EP2983709A1 (de) * 2013-04-08 2016-02-17 Academisch Medisch Centrum Miltefosin oder perifosin zur verwendung bei der behandlung von entzündlicher darmerkrankung
EP3193843A1 (de) 2014-09-17 2017-07-26 Steerlife India Private Limited Brausezusammensetzung und verfahren zur herstellung davon
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
WO2020208230A1 (en) 2019-04-12 2020-10-15 Oblita Therapeutics Bvba Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
CA1338627C (en) * 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
CZ20002596A3 (cs) 2000-10-11
KR20010034311A (ko) 2001-04-25
WO1999037289A1 (en) 1999-07-29
BR9814772A (pt) 2000-10-24
SK284839B6 (sk) 2005-12-01
NO20003674L (no) 2000-07-18
NZ505648A (en) 2002-10-25
US6544551B1 (en) 2003-04-08
HUP0004363A2 (hu) 2001-04-28
EP1051159A1 (de) 2000-11-15
AU756805B2 (en) 2003-01-23
PL189654B1 (pl) 2005-09-30
SK9862000A3 (en) 2000-11-07
CA2318260A1 (en) 1999-07-29
DE69804865T2 (de) 2002-11-07
JP2002501015A (ja) 2002-01-15
ES2175663T3 (es) 2002-11-16
IL136196A0 (en) 2001-05-20
KR100517399B1 (ko) 2005-09-28
SI1051159T1 (en) 2002-10-31
HUP0004363A3 (en) 2002-12-28
CZ299229B6 (cs) 2008-05-21
PL342838A1 (en) 2001-07-16
CN1283111A (zh) 2001-02-07
AU6212198A (en) 1999-08-09
TR200001717T2 (tr) 2000-11-21
UA68372C2 (en) 2004-08-16
DE69804865D1 (de) 2002-05-16
CA2318260C (en) 2006-11-21
IL136196A (en) 2004-07-25
EP1051159B1 (de) 2002-04-10
CN100413492C (zh) 2008-08-27
ATE215817T1 (de) 2002-04-15
NO20003674D0 (no) 2000-07-18
PT1051159E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
DK1051159T3 (da) Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis
EP1049459A4 (de) Orale flüssige zusammensetzungen
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
MY122411A (en) Controlled release galantamine composition
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
JO2663B1 (en) Abandronate is a large dose
BR0009476A (pt) Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
BR0005392A (pt) Composição de dhea e processo
SE8006550L (sv) Farmakologisk komposition, samt sett for dess framstellning
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
ES2165727T3 (es) Composiciones de administracion por via oral con baja dosificacion de proteinas citotoxicas.
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler
UA32939A (uk) Сульфокамфокаїн, спосіб його виготовлення і спосіб підготовки обладнання для виготовлення сульфокамфокаїну
UA30970A (uk) Спосіб лікування пульпіту
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1